ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

13.63
-0.05
(-0.37%)
At close: September 18 4:00PM
13.63
0.01
( 0.07% )
After Hours: 5:30PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
13.63
Bid
13.00
Ask
14.10
Volume
64,147
13.37 Day's Range 14.11
7.12 52 Week Range 17.30
Market Cap
Previous Close
13.68
Open
13.59
Last Trade Time
16:02:59
Financial Volume
$ 887,446
VWAP
13.8346
Average Volume (3m)
280,622
Shares Outstanding
17,594,977
Dividend Yield
-
PE Ratio
-9.55
Earnings Per Share (EPS)
-1.43
Revenue
116.88M
Net Profit
-25.09M

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was $13.68. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of $ 7.12 to $ 17.30.

Rigel Pharmaceuticals currently has 17,594,977 shares outstanding. The market capitalization of Rigel Pharmaceuticals is $240.70 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -9.55.

RIGL Latest News

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Rigel to Present at the 2024 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 /PRNewswire/ -- Rigel...

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024 First trial in Rigel's...

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 3, 2024 Kissei gains...

Rigel to Participate in Upcoming September Investor Conferences

Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 /PRNewswire/ -- Rigel...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.866.7345340642112.7714.212.669977013.33814244CS
40.987.7470355731212.6514.2129684013.216784CS
125.4266.01705237528.2114.27.48432806229.18696605CS
260.030.22058823529413.615.057.484395545810.66321193CS
522.5322.792792792811.117.37.12104743011.1892681CS
156-24.47-64.225721784838.139.056.4227825814.66589717CS
260-2.97-17.891566265116.6556.4252334322.77083445CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
XCURExicure Inc
$ 6.15
(168.56%)
8.36M
VEROVenus Concept Inc
$ 1.09
(116.92%)
14.23M
ZEOZeo Energy Corporation
$ 1.58
(38.60%)
107.2k
VINOGaucho Group Holdings Inc
$ 5.34
(18.93%)
700
TBIOTelesis Bio Inc
$ 1.61
(18.38%)
790.8k
SMFLSmart for Life Inc
$ 0.4131
(-47.04%)
2.66M
PGNYProgyny Inc
$ 18.20
(-25.53%)
151.14k
RGFReal Good Food Company Inc
$ 0.3701
(-13.93%)
28.2k
OMEXOdyssey Marine Exploration Inc
$ 1.22
(-12.86%)
4.98M
CRMTAmericas Car Mart Inc
$ 43.75
(-12.43%)
7.11k
VEROVenus Concept Inc
$ 1.09
(116.92%)
14.23M
EJHE Home Household Service Holdings Ltd
$ 0.1125
(6.13%)
10.55M
XCURExicure Inc
$ 6.15
(168.56%)
8.36M
NVDANVIDIA Corporation
$ 114.0305
(0.58%)
7.1M
OMEXOdyssey Marine Exploration Inc
$ 1.22
(-12.86%)
4.98M

RIGL Discussion

View Posts
dcaf7 dcaf7 5 months ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 5 months ago
RIGL under $2
👍️0
Monksdream Monksdream 6 months ago
RIGL under $2
👍️0
dcaf7 dcaf7 6 months ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 6 months ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 7 months ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 1 year ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 1 year ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 1 year ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 1 year ago
Better be good.
👍️0
bme bme 1 year ago
Ugly.
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
base
👍️0
bme bme 1 year ago
What a shoot! Amazing.
👍️0
bme bme 1 year ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 1 year ago
nice fins
👍️0
The Night Stalker The Night Stalker 1 year ago
gem
👍️0
The Night Stalker The Night Stalker 1 year ago
gem
👍️0
The Night Stalker The Night Stalker 1 year ago
easy
👍️0
bme bme 1 year ago
Nice spike AH today.
👍️0
bme bme 1 year ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 1 year ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
bme bme 1 year ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 1 year ago
quite the dip
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 1 year ago
ready
👍️0
The Night Stalker The Night Stalker 1 year ago
red to green
👍️0
The Night Stalker The Night Stalker 1 year ago
red to green
👍️0
bme bme 1 year ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 1 year ago
beauty
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
bme bme 2 years ago
Expect Q4 filing this week?
👍️0
bme bme 2 years ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 years ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 years ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 years ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 years ago
RIGL news out
👍️0
bme bme 2 years ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 years ago
Just like ABQQ. Right?
👍️0
subslover subslover 2 years ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 years ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 years ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 years ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 years ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 years ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

Delayed Upgrade Clock